Cantor Fitzgerald reaffirmed their overweight rating on shares of ACADIA Pharmaceuticals (NASDAQ:ACAD – Free Report) in a research note published on Friday, Benzinga reports. The firm currently has a $42.00 price target on the biopharmaceutical company’s stock. ACAD has been the topic of several other research reports. Stifel Nicolaus raised their price target on shares […]
ACADIA Pharmaceuticals (NASDAQ:ACAD) Lifted to Buy at StockNews.com theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.
Robert W. Baird initiated coverage on shares of ACADIA Pharmaceuticals (NASDAQ:ACAD – Free Report) in a report released on Tuesday morning, Marketbeat Ratings reports. The firm issued an outperform rating and a $40.00 price objective on the biopharmaceutical company’s stock. Other equities analysts have also recently issued reports about the company. Citigroup initiated coverage on […]
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD – Free Report) – Research analysts at Zacks Research raised their Q4 2024 EPS estimates for shares of ACADIA Pharmaceuticals in a note issued to investors on Wednesday, January 31st. Zacks Research analyst A. Chakraborty now anticipates that the biopharmaceutical company will post earnings per share of $0.24 for the quarter, […]
Needham & Company LLC upgraded shares of ACADIA Pharmaceuticals (NASDAQ:ACAD – Free Report) from a hold rating to a buy rating in a report published on Wednesday morning, Marketbeat reports. They currently have $37.00 price objective on the biopharmaceutical company’s stock. A number of other brokerages also recently commented on ACAD. Deutsche Bank Aktiengesellschaft began […]